EMR Stock Analysis: Emerson Electric | NYSE

Specialty Industrial Machinery | NYSE, USA | Market Cap: 90.626m USD | 12M Return: 22.2% | US2910111044 | Charts, Fundamentals & Technical Analysis

Control Valves, Process Instrumentation, Industrial Automation, Test Measurement
Total Rating 52
Safety 87
Buy Signal -0.20
Specialty Industrial Machinery
Industry Rotation: +8.2
Market Cap: 90.6B
Avg Turnover: 425M
Risk 3d forecast
Volatility33.3%
VaR 5th Pctl5.60%
VaR vs Median2.44%
Reward TTM
Sharpe Ratio0.64
Rel. Str. IBD59.2
Rel. Str. Peer Group57
Character TTM
Beta1.454
Beta Downside1.218
Hurst Exponent0.498
Drawdowns 3y
Max DD29.62%
CAGR/Max DD0.69
CAGR/Mean DD2.58
EPS (Earnings per Share) EPS (Earnings per Share) of EMR over the last years for every Quarter: "2021-06": 1.09, "2021-09": 1.21, "2021-12": 1.05, "2022-03": 1.29, "2022-06": 1.38, "2022-09": 1.53, "2022-12": 0.78, "2023-03": 1.09, "2023-06": 1.29, "2023-09": 1.29, "2023-12": 1.22, "2024-03": 1.36, "2024-06": 1.43, "2024-09": 1.48, "2024-12": 1.38, "2025-03": 1.48, "2025-06": 1.52, "2025-09": 1.62, "2025-12": 1.46, "2026-03": 1.54, "2026-06": 1.71,
EPS CAGR: 11.70%
EPS Trend: 95.9%
Last SUE: 0.84
Qual. Beats: 0
Revenue Revenue of EMR over the last years for every Quarter: 2021-06: 4697, 2021-09: 4947, 2021-12: 3156, 2022-03: 3291, 2022-06: 3465, 2022-09: 5360, 2022-12: 3373, 2023-03: 3756, 2023-06: 3946, 2023-09: 4090, 2023-12: 4117, 2024-03: 4376, 2024-06: 4380, 2024-09: 4619, 2024-12: 4175, 2025-03: 4432, 2025-06: 4553, 2025-09: 4855, 2025-12: 4346, 2026-03: 4562, 2026-06: 4873,
Rev. CAGR: 6.58%
Rev. Trend: 93.9%
Last SUE: 1.49
Qual. Beats: 1

Warnings

Choppy
Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan -0.8% 8
Feb +1.4% 5
Mar +0.1% 7
Apr -1.7% 11
May -0.0% 7
Jun -0.8% 8
Jul +3.2% 36
Aug -2.9% 15
Sep -1.0% 2
Oct -1.8% 14
Nov +1.5% 33
Dec +0.4% 16

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: EMR Emerson Electric

Emerson Electric Co. (EMR) is a global technology and software company headquartered in Saint Louis, Missouri, that provides industrial automation, process control, and measurement solutions across the Americas, Asia, the Middle East, Africa, and Europe. The company operates through six business segments-Final Control, Measurement & Analytical, Discrete Automation, Safety & Productivity, Control Systems & Software, and Test & Measurement-offering products such as control valves, intelligent instrumentation, solenoid and pneumatic valves, process control software (DeltaV and Ovation), professional and consumer tools, and automated test systems. Emerson serves a diverse customer base spanning process industries (oil & gas, chemicals, power), discrete manufacturing, and infrastructure, marketing under well-known brands such as Fisher, Rosemount, ASCO, Branson, and RIDGID.

Listed on the NYSE as a Large Cap stock in the Industrials sector (Electrical Components & Equipment sub-industry), Emerson has been in operation since its incorporation in 1890, giving it more than 130 years of industrial heritage. The companys business model combines hardware products (valves, instruments, tools) with higher-margin software and automation solutions, an increasingly important strategic focus as manufacturers and process operators pursue digitalization and operational efficiency.

Headlines to Watch Out For
  • Process automation demand tracks energy and chemicals capital spending
  • Test and Measurement segment benefits from AI data center infrastructure investment
  • AspenTech and DeltaV software expand recurring revenue mix and margins
Piotroski VR-10 (Strict) 6.5
Net Income: 2.58b TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 4.82 > 1.0
NWC/Revenue: -5.99% < 20% (prev -9.34%; Δ 3.34% < -1%)
CFO/TA 0.13 > 3% & CFO 5.39b > Net Income 2.58b
Net Debt (11.1b) to EBITDA (5.14b): 2.15 < 3
Current Ratio: 0.90 > 1.5 & < 3
Outstanding Shares: last quarter (561.1m) vs 12m ago -0.64% < -2%
Gross Margin: 53.16% > 18% (prev 52.70%; Δ 0.46% > 0.5%)
Asset Turnover: 43.99% > 50% (prev 41.82%; Δ 2.18% > 0%)
Interest Coverage Ratio: 6.93 > 6 (EBIT TTM 3.83b / Interest Expense TTM 553.0m)
Altman Z'' 4.63
A: -0.03 (Total Current Assets 9.65b - Total Current Liabilities 10.8b) / Total Assets 42.2b
B: 0.99 (Retained Earnings 41.6b / Total Assets 42.2b)
C: 0.09 (EBIT TTM 3.83b / Avg Total Assets 42.4b)
D: 0.93 (Book Value of Equity 20.4b / Total Liabilities 21.8b)
Altman-Z'' = 4.63 = AA
Beneish M -3.02
DSRI: 1.00 (Receivables 3.06b/2.91b, Revenue 18.6b/17.8b)
GMI: 0.99 (GM 52.70% / 53.16%)
AQI: 0.98 (AQ_t 0.70 / AQ_t-1 0.72)
SGI: 1.05 (Revenue 18.6b / 17.8b)
TATA: -0.07 (NI 2.58b - CFO 5.39b) / TA 42.2b)
Beneish M = -3.02 (Cap -4..+1) = AA
What is the price of EMR shares?

As of August 11, 2026, the stock is trading at USD 158.71 with a total of 2,278,296 shares traded. Over the past week, the price has changed by +2.49%, over one month by +14.28%, over three months by +14.29% and over the past year by +22.23%.

Current recommended Stop Loss: 147.60 (which is 7% or 2.2 ATR below the current price).

Is EMR a buy, sell or hold?

Emerson Electric has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy EMR.

  • StrongBuy: 19
  • Buy: 3
  • Hold: 6
  • Sell: 1
  • StrongSell: 1

What are the forecasts/targets for the EMR price?
Analysts Target Price 163.5 3%
Emerson Electric (EMR) - Fundamental Data Overview as of 07 August 2026
Market Cap USD = 90.6b (90.6b USD * 1.0 USD.USD)
P/E Trailing = 34.7158
P/E Forward = 22.1729
P/S = 4.8629
P/B = 4.3656
P/EG = 2.2153
Revenue TTM = 18.6b USD
EBIT TTM = 3.83b USD
EBITDA TTM = 5.14b USD
Long Term Debt = 7.53b USD (from longTermDebt, last quarter)
Short Term Debt = 5.59b USD (from shortTermDebt, last quarter)
Debt = 13.3b USD (from shortLongTermDebtTotal, last quarter) + Leases 142.0m
Net Debt = 11.1b USD (calculated: Debt 13.3b - CCE 2.18b)
Enterprise Value = 102b USD (90.6b + Debt 13.3b - CCE 2.18b)
Interest Coverage Ratio = 6.93 (Ebit TTM 3.83b / Interest Expense TTM 553.0m)
EV/FCF = 21.38x (Enterprise Value 102b / FCF TTM 4.76b)
FCF Yield = 4.68% (FCF TTM 4.76b / Enterprise Value 102b)
FCF Margin = 25.52% (FCF TTM 4.76b / Revenue TTM 18.6b)
Net Margin = 13.83% (Net Income TTM 2.58b / Revenue TTM 18.6b)
Gross Margin = 53.16% ((Revenue TTM 18.6b - Cost of Revenue TTM 8.73b) / Revenue TTM)
Gross Margin QoQ = 54.48% (prev 53.09%)
Tobins Q-Ratio = 2.41 (Enterprise Value 102b / Total Assets 42.2b)
Interest Expense / Debt = 4.17% (Interest Expense 553.0m / Debt 13.3b)
Taxrate = 21.40% (702.0m / 3.28b)
NOPAT = 3.01b (EBIT 3.83b * (1 - 21.40%))
Current Ratio = 0.90 (Total Current Assets 9.65b / Total Current Liabilities 10.8b)
Debt / Equity = 0.65 (Debt 13.3b / totalStockholderEquity, last quarter 20.4b)
Debt / EBITDA = 2.15 (Net Debt 11.1b / EBITDA 5.14b)
Debt / FCF = 2.33 (Net Debt 11.1b / FCF TTM 4.76b)
Total Stockholder Equity = 20.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.08% (Net Income 2.58b / Total Assets 42.2b)
RoE = 12.69% (Net Income TTM 2.58b / Total Stockholder Equity 20.3b)
RoCE = 13.77% (EBIT 3.83b / Capital Employed (Equity 20.3b + L.T.Debt 7.53b))
RoIC = 8.35% (NOPAT 3.01b / Invested Capital 36.1b)
WACC = 10.10% (E(90.6b)/V(104b) * Re(11.10%) + D(13.3b)/V(104b) * Rd(4.17%) * (1-Tc(0.21)))
Discount Rate = 11.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.38 | Cagr: -1.01%
[DCF] Terminal Value 72.52% ; FCFF base≈3.95b ; Y1≈4.53b ; Y5≈6.66b
[DCF] Fair Price = 117.4 (EV 76.6b - Net Debt 11.1b = Equity 65.5b / Shares 557.8m; r=10.10% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.90 | EPS CAGR: 11.70% | SUE: 0.84 | # QB: 0
Revenue Correlation: 93.94 | Revenue CAGR: 6.58% | SUE: 1.49 | # QB: 1
EPS current Quarter (2026-12-31): EPS=1.60 | Chg30d=+0.38% | Revisions=-25% | Analysts=9
EPS current Year (2026-09-30): EPS=6.50 | Chg30d=-0.19% | Revisions=+0% | GrowthEPS=+8.3% | GrowthRev=+4.5%
EPS next Year (2027-09-30): EPS=7.17 | Chg30d=-0.13% | Revisions=+0% | GrowthEPS=+10.3% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: -7% (up=5, down=6)